English
Regional settings| Spread | 0.06 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.88 |
| Open | 0.84 |
| 1-Year Change | -51.72% |
| Day's Range | 0.77 - 0.85 |
OptiNose, Inc. is a specialty pharmaceutical company that is focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company’s products candidates include XHANCE (fluticasone propionate) and ONZETRA Xsail. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 mcg, is therapeutic utilizing its proprietary exhalation delivery system (EDS) device that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.
BRIEF: For the fiscal year ended 31 December 2021, OptiNose Inc revenues increased 52% to $74.7M. Net loss decreased 18% to $82.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 13% to $1.1M (expense), Stock-based Compensation in SGA decrease of 1% to $8.9M (expense).
